{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T06:41:15Z","timestamp":1772088075354,"version":"3.50.1"},"reference-count":109,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2007,5,26]],"date-time":"2007-05-26T00:00:00Z","timestamp":1180137600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2008,4]]},"DOI":"10.1007\/s10549-007-9610-z","type":"journal-article","created":{"date-parts":[[2007,5,25]],"date-time":"2007-05-25T11:46:44Z","timestamp":1180093604000},"page":"319-331","source":"Crossref","is-referenced-by-count":54,"title":["Gemcitabine in the management of metastatic breast cancer: a systematic review"],"prefix":"10.1007","volume":"108","author":[{"given":"Susan","family":"Dent","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Messersmith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maureen","family":"Trudeau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,5,26]]},"reference":[{"issue":"8","key":"9610_CR1","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1200\/JCO.2003.09.081","volume":"21","author":"ML Citron","year":"2003","unstructured":"Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ et\u00a0al (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination therapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741\/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21(8):1431\u20131439","journal-title":"J Clin Oncol"},{"issue":"6","key":"9610_CR2","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1200\/JCO.2003.02.063","volume":"21","author":"IC Henderson","year":"2003","unstructured":"Henderson IC, Berry DA, Demetri GD, Cirrincione C, Goldstein LJ, Martion S et\u00a0al (2003) Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21(6):976\u2013983","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"9610_CR3","first-page":"S16, A27","volume":"88","author":"H Roche","year":"2005","unstructured":"Roche H, Fumoleau P, Spielmann M, et\u00a0al (2005) Five years analysis of the PACS 01 trial: 6 cycles of FEC100 vs. 3 cycles of FEC100 followed by 3 cycles of docetaxel (D) for the adjuvant treatment node positive cancer. Breast Cancer Res Treat 88(Suppl 1):S16, A27","journal-title":"Breast Cancer Res Treat"},{"key":"9610_CR4","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1056\/NEJMoa043681","volume":"352","author":"M Martin","year":"2005","unstructured":"Martin M, Pienkowski T, Mackey J, Pawlicki M, Gustalla JP, Weaver C et\u00a0al (2005) Adjuvant docetaxel for node-positive breast cancer. New Engl J Med 352:2302\u20132313","journal-title":"New Engl J Med"},{"key":"9610_CR5","doi-asserted-by":"crossref","unstructured":"Chan S, Romieu G, Huober J, Delozier T, Tubiana-Hulin M, Lluch A et\u00a0al (2005) Gemcitabine plus docetaxel (GD) versus capecitabine plus docetaxel (CD) for anthracycline-pretreated metastatic breast cancer (MBC) patients (pts): results of a European phase III study [slides on the internet] [abstract 581]. In: 2005 ASCO Annual Meeting. Available from: http:\/\/www.asco.org\/portal\/site\/ASCO .. Cited 16 Sep 2005","DOI":"10.1200\/jco.2005.23.16_suppl.581"},{"issue":"16 Suppl","key":"9610_CR6","doi-asserted-by":"crossref","first-page":"A581","DOI":"10.1200\/jco.2005.23.16_suppl.581","volume":"23","author":"S Chan","year":"2005","unstructured":"Chan S, Romieu G, Huober J, et\u00a0al (2005) Gemcitabine plus docetaxel (GD) versus capecitabine plus docetaxel (CD) for anthracycline-pretreated metastatic breast cancer (MBC) patients (pts): results of a European phase III study. J Clin Oncol 23(16 Suppl):A581","journal-title":"J Clin Oncol"},{"key":"9610_CR7","first-page":"7, A25","volume":"22","author":"J O\u2019Shaughnessy","year":"2003","unstructured":"O\u2019Shaughnessy J, Nag S, Calderillo-Ruiz G et\u00a0al (2003) Gemcitabine plus paclitaxel (GT) versus paclitaxel (T) as first-line treatment for anthracycline pre-treated metastatic breast cancer (MBC): interim results of a global phase III study. Proc Am Soc Clin Onc 22:7, A25","journal-title":"Proc Am Soc Clin Onc"},{"key":"9610_CR8","unstructured":"O\u2019Shaughnessy J, Nag S, Calderillo-Ruiz G, Jordaan J, Llombart A, Pluzanska A et\u00a0al (2003) Gemcitabine plus paclitaxel (GT) versus paclitaxel (T) as first-line treatment for anthracycline pre-treated metastatic breast cancer (MBC): interim results of a global phase III study [slides on the Internet] [abstract 25]. In: 2003 ASCO Annual Meeting. Available from: http:\/\/www.asco.org\/portal\/site\/ASCO . Cited 11 May 2005"},{"issue":"14 Suppl","key":"9610_CR9","doi-asserted-by":"crossref","first-page":"A621","DOI":"10.1200\/jco.2004.22.14_suppl.621","volume":"22","author":"C Moinpour","year":"2004","unstructured":"Moinpour C, Wu J, Donaldson G, et\u00a0al (2004) Gemcitabine plus paclitaxel (GT) versus paclitaxel (T) as first-line treatment for anthracycline pre-treated metastatic breast cancer (MBC): quality of life (QoL) and pain palliation results from the global phase III study. J Clin Oncol 22(14 Suppl):A621","journal-title":"J Clin Oncol"},{"key":"9610_CR10","doi-asserted-by":"crossref","unstructured":"Moinpour C, Wu J, Donaldson G, Liepa A, Melemed A, Oshaughnessy J et\u00a0al (2004) Gemcitabine plus paclitaxel (GT) versus paclitaxel (T) as first-line treatment for anthracycline pre-treated metastatic breast cancer (MBC): quality of life (QoL) and pain palliation results from the global phase III study [slides on the Internet] [abstract 621]. In: 2004 ASCO Annual Meeting. Available from: http:\/\/www.asco.org\/portal\/site\/ASCO . Cited 11 May 2005","DOI":"10.1200\/jco.2004.22.90140.621"},{"issue":"14 Suppl","key":"9610_CR11","doi-asserted-by":"crossref","first-page":"A510","DOI":"10.1200\/jco.2004.22.14_suppl.510","volume":"22","author":"KS Albain","year":"2004","unstructured":"Albain KS, Nag S, Calderillo-Ruiz G et\u00a0al (2004) Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): first report of overall survival. J Clin Oncol 22(14 Suppl):A510","journal-title":"J Clin Oncol"},{"key":"9610_CR12","unstructured":"Albain KS, Nag S, Calderillo-Ruiz G, Jordaan JP, Llombart A, Pluzanska A et\u00a0al (2004) Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): First report of overall survival [slides on the Internet] [abstract 510]. In: 2004 ASCO Annual Meeting. Available from: http:\/\/www.asco.org\/portal\/site\/ASCO . Cited 11 May 2005."},{"key":"9610_CR13","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1093\/annonc\/mdi181","volume":"16","author":"O Feher","year":"2005","unstructured":"Feher O, Vodvarka P, Jassem J, Morack G, Advani SH, Khoo K et\u00a0al (2005) First-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: a multicenter, randomized, phase III study. Ann Oncol 16:899\u2013908","journal-title":"Ann Oncol"},{"issue":"7","key":"9610_CR14","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1200\/JCO.2005.12.106","volume":"23","author":"C Zielinski","year":"2005","unstructured":"Zielinski C, Beslija S, Mrsic-Krmpotic Z, Welnicka-Jaskiewicz M, Wiltschke C, Kahan Z et\u00a0al (2005) Gemcitabine, epirubicin, and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: a Central European Cooperative Oncology Group international, multicenter, prospective, randomized phase III trial. J Clin Oncol 23(7):1401\u20131408","journal-title":"J Clin Oncol"},{"key":"9610_CR15","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1016\/j.ejca.2006.05.001","volume":"42","author":"KS Khoo","year":"2006","unstructured":"Khoo KS, Zaidi SHM, Srimuninnimit V, Song S, Nair R, Ngelangel CA et\u00a0al (2006) Gemcitabine and split-dose paclitaxel or docetaxel in metastatic breast cancer: a randomised phase II study. Eur J Cancer 42:1797\u20131806","journal-title":"Eur J Cancer"},{"issue":"5","key":"9610_CR16","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S1359-6349(05)82020-8","volume":"3","author":"S Chan","year":"2005","unstructured":"Chan S (2005) Gemcitabine plus docetaxel versus capecitabine plus docetaxel for patients with anthracycline-pretreated metastatic breast cancer: a review of the results of a European phase III trial. EJC Supplements 3(5):17\u201321","journal-title":"EJC Supplements"},{"issue":"Suppl 4","key":"9610_CR17","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/S0305-7372(05)80004-0","volume":"31","author":"C Levy","year":"2005","unstructured":"Levy C, Fumoleau P (2005) Gemcitabine plus docetaxel: a new treatment option for anthracycline pretreated metastatic breast cancer patients? Cancer Treat Rev 31(Suppl 4):S17\u2013S22","journal-title":"Cancer Treat Rev"},{"issue":"18S","key":"9610_CR18","doi-asserted-by":"crossref","first-page":"A682","DOI":"10.1200\/jco.2006.24.18_suppl.682","volume":"24","author":"P Fumoleau","year":"2006","unstructured":"Fumoleau P, Romieu G, Chan S et\u00a0al (2006) Impact of symptoms and toxicity on quality of life: exploratory analysis of gemcitabine plus docetaxel vs. capecitabine plus docetaxel in metastatic breast cancer. J Clin Oncol 24(18S):A682","journal-title":"J Clin Oncol"},{"key":"9610_CR19","unstructured":"Fumoleau P, Romieu G, Chan S, Hueber J, Tubiana-Hulin M, Schneeweiss A et\u00a0al (2006) Impact of symptoms and toxicity on quality of life (QoL): exploratory analysis of gemcitabine plus docetaxel (GD) versus capecitabine plus docetaxel (CD) in metastatic breast cancer (MBC) [slides on the Internet] [abstract 682]. In: 2006 ASCO Annual Meeting. Available from: http:\/\/www.asco.org\/portal\/site\/ASCO . Cited 01 Oct 2006"},{"issue":"1","key":"9610_CR20","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1159\/000048240","volume":"62","author":"M Blackstein","year":"2002","unstructured":"Blackstein M, Vogel CL, Ambinder R, Cowan J, Iglesias J, Melemed A (2002) Gemcitabine as first-line therapy in patients with metastatic breast cancer: a phase II trial. Oncology 62(1):2\u20138","journal-title":"Oncology"},{"issue":"2","key":"9610_CR21","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/00001813-199902000-00003","volume":"10","author":"K Possinger","year":"1999","unstructured":"Possinger K, Kaufmann M, Coleman R, Stuart NSA, Helsing M, Ohnmacht U, et\u00a0al (1999) Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer. Anticancer Drugs 10(2):155\u2013162","journal-title":"Anticancer Drugs"},{"issue":"11","key":"9610_CR22","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1200\/JCO.1995.13.11.2731","volume":"13","author":"J Carmichael","year":"1995","unstructured":"Carmichael J, Possinger K, Phillip P, Beykirch M, Kerr H, Walling J et\u00a0al (1995) Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol 13(11):2731\u20132736","journal-title":"J Clin Oncol"},{"issue":"7","key":"9610_CR23","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/00001813-199908000-00001","volume":"10","author":"P Schmid","year":"1999","unstructured":"Schmid P, Akrivakis K, Flath B, Grosse Y, Sezer O, Mergenthaler HG et\u00a0al (1999) Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer. Anticancer Drugs 10(7):625\u2013631","journal-title":"Anticancer Drugs"},{"key":"9610_CR24","doi-asserted-by":"crossref","unstructured":"El Serafy M, El Kohdary A, El Zawahry H et\u00a0al (2003) Gemcitabine plus doxorubicin as first-line treatment in advanced or metastatic breast cancer (MBC) [abstract]. Proc Am Soc Clin Onc 22:50 [A199]","DOI":"10.1200\/jco.2004.22.90140.769"},{"issue":"13","key":"9610_CR25","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1200\/JCO.2000.18.13.2545","volume":"18","author":"G Perez-Manga","year":"2000","unstructured":"Perez-Manga G, Lluch A, Alba E, Moreno-Nogueira JA, Palomero M, Garcia-Conde J et\u00a0al (2000) Gemcitabine in combination with doxorubicin in advanced breast cancer: final results of a phase II pharmacokinetic trial. J Clin Oncol 18(13):2545\u20132552","journal-title":"J Clin Oncol"},{"issue":"17","key":"9610_CR26","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1200\/JCO.2003.03.111","volume":"21","author":"E Rivera","year":"2003","unstructured":"Rivera E, Valero V, Arun B, Royce M, Adinin R, Hoelzer K et\u00a0al (2003) Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer. J Clin Oncol 21(17):3249\u20133254","journal-title":"J Clin Oncol"},{"issue":"14 Suppl","key":"9610_CR27","first-page":"A813","volume":"22","author":"A Fabi","year":"2004","unstructured":"Fabi A, Papaldo P, Ciccarese M et\u00a0al (2004) Pegylated liposomal doxorubicin (PLD) and gemcitabine (G) in metastatic breast cancer (MBC) patients: a phase II study. J Clin Oncol ASCO Ann Meet Proc (Post-Meet Ed):22(14 Suppl):A813","journal-title":"J Clin Oncol ASCO Ann Meet Proc (Post-Meet Ed):"},{"key":"9610_CR28","unstructured":"Campone M, Viens P, Dieras V et\u00a0al (2001) Gemzar (G) and epirubicin (E) in patients (pts) with metastatic breast cancer (MBC): results of a phase II trial [abstract]. Proc Am Soc Clin Onc 20(2):48b [A1940]"},{"issue":"4","key":"9610_CR29","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/01.coc.0000128527.95562.ae","volume":"27","author":"H Hausmaninger","year":"2004","unstructured":"Hausmaninger H, Morack G, Heinrich B, Wallwiener D, Hoffken K, Buksmaui S et\u00a0al (2004) Gemcitabine combined with epirubicin in the treatment of patients with locally advanced or metastatic breast cancer: a phase II study. Am J Clin Oncol 27(4):429\u2013435","journal-title":"Am J Clin Oncol"},{"key":"9610_CR30","first-page":"1051","volume":"8","author":"GV Kornek","year":"2002","unstructured":"Kornek GV, Haider K, Kwasny W, Raderer M, Schull B, Payrits T et\u00a0al (2002) Treatment of advanced breast cancer with docetaxel and gemcitabine with and without human granulocyte colony-stimulating factor. Clin Cancer Res 8:1051\u20131056","journal-title":"Clin Cancer Res"},{"key":"9610_CR31","unstructured":"Garle PA, Calvo L, Mayordomo JI et\u00a0al (2003) Gemcitabine and docetaxel given every other week as first-line therapy for metastatic breast cancer (MBC): Final results of a phase II study conducted within the Breast Cancer Investigation Spanish Group (GEICAM). Proc Am Soc Clin Onc 22:50 [A201]"},{"key":"9610_CR32","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1159\/000086986","volume":"68","author":"S Palmeri","year":"2005","unstructured":"Palmeri S, Vaglica M, Spada S, Filippelli G, Farris A, Palmeri L et\u00a0al (2005) Weekly docetaxel and gemcitabine as first-line treatment for metastatic breast cancer: results of a multicenter phase II study. Oncology 68:438\u2013445","journal-title":"Oncology"},{"key":"9610_CR33","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1159\/000081325","volume":"67","author":"D Mavroudis","year":"2004","unstructured":"Mavroudis D, Malamos N, Polyzos A, Kouroussis C, Christophilakis Ch, Varthalitis I et\u00a0al (2004) Front-line chemotherapy with docetaxel and gemcitabine administered every two weeks in patients with metastatic breast cancer: a multicenter phase II study. Oncology 67:250\u2013256","journal-title":"Oncology"},{"issue":"6","key":"9610_CR34","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3109\/07357900009012188","volume":"18","author":"G Fountzilas","year":"2000","unstructured":"Fountzilas G, Nicolaides C, Bafaloukos D, Kalogera-Fountzila A, Kalofonos H, Samelis G et\u00a0al (2000) Docetaxel and gemcitabine in anthracycline-resistant advanced breast cancer: a Hellenic Cooperative Oncology Group Phase II study. Cancer Invest 18(6):503\u2013509","journal-title":"Cancer Invest"},{"issue":"9","key":"9610_CR35","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1023\/A:1012247311419","volume":"12","author":"LR Laufman","year":"2001","unstructured":"Laufman LR, Spiridonidis CH, Pritchard J, Roach R, Zangmeister J, Larrimer N et\u00a0al (2001) Monthly docetaxel and weekly gemcitabine in metastatic breast cancer: a phase II trial. Ann Oncol 12(9):1259\u20131264","journal-title":"Ann Oncol"},{"key":"9610_CR36","unstructured":"Genot J, Tubiana-Hulin M, Tubiana-Mathieu M et\u00a0al (2002) Gemcitabine and paclitaxel in metastatic breast cancer: a phase II study in the first line setting [abstract]. Proc Am Soc Clin Onc 21(2):48b [A2002]"},{"issue":"1","key":"9610_CR37","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000076330","volume":"66","author":"C Delfino","year":"2004","unstructured":"Delfino C, Caccia G, Gonzales LR, Mickiewicz E, Rodger J, Balbiani L, et\u00a0al (2004) Gemcitabine plus paclitaxel as first-line chemotherapy for patients with advanced breast cancer. Oncology 66(1):18\u201323","journal-title":"Oncology"},{"issue":"2","key":"9610_CR38","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1093\/annonc\/mdh048","volume":"15","author":"R Colomer","year":"2004","unstructured":"Colomer R, Llombart-Cussac A, Lluch A, Barnadas A, Ojeda B, Caranana V et\u00a0al (2004) Biweekly paclitaxel plus gemcitabine in advanced breast cancer: Phase II trial and predictive value of HER2 extracellular domain. Ann Oncol 15(2):201\u2013206","journal-title":"Ann Oncol"},{"issue":"16 Suppl","key":"9610_CR39","doi-asserted-by":"crossref","first-page":"A713","DOI":"10.1200\/jco.2005.23.16_suppl.713","volume":"23","author":"Z Alauddin","year":"2005","unstructured":"Alauddin Z, Shaharyar A (2005) Gemcitabine and cisplatin combination chemotherapy as first-line treatment in patients with metastatic breast cancer. J Clin Oncol 23(16 Suppl):A713","journal-title":"J Clin Oncol"},{"key":"9610_CR40","first-page":"A1988","volume":"20","author":"GC Ruiz","year":"2001","unstructured":"Ruiz GC, de la Pena HF, Meza FA et\u00a0al (2001) A phase II study of gemcitabine plus cisplatin in metastatic breast cancer (MBC). Proc Am Soc Clin Onc 20:A1988","journal-title":"Proc Am Soc Clin Onc"},{"key":"9610_CR41","unstructured":"Xu B, Li K, Liu D (2003) Phase II trial of gemcitabine and cisplatin in anthracycline-resistant metastatic breast cancer. Proc Am Soc Clin Onc 22:53 [A211]"},{"issue":"2","key":"9610_CR42","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/01.coc.0000144815.54746.d0","volume":"28","author":"PA Burch","year":"2005","unstructured":"Burch PA, Mailliard JA, Hillman DW, Perez EA, Krook JE, Rowland KM, et\u00a0al (2005) Phase II study of gemcitabine plus cisplatin in patients with metastatic breast cancer: a North Central Cancer Treatment Group trial. Am J Clin Oncol 28(2):195\u2013200","journal-title":"Am J Clin Oncol"},{"issue":"3","key":"9610_CR43","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1023\/A:1006136112585","volume":"55","author":"K Haider","year":"1999","unstructured":"Haider K, Kornek GV, Kwasny W, Weinlander G, Valencak J, Lang F et\u00a0al (1999) Treatment of advanced breast cancer with gemcitabine and vinorelbine plus human granulocyte colony-stimulating factor. Breast Cancer Res Treat 55(3):203\u2013211","journal-title":"Breast Cancer Res Treat"},{"issue":"16 Suppl","key":"9610_CR44","doi-asserted-by":"crossref","first-page":"A741","DOI":"10.1200\/jco.2005.23.16_suppl.741","volume":"23","author":"C Gennatas","year":"2005","unstructured":"Gennatas C, Mouratidou D, Tsavaris N et\u00a0al (2005) Gemcitabine in combination with vinorelbine for heavily pretreated advanced breast cancer. J Clin Oncol 23(16 Suppl):A741","journal-title":"J Clin Oncol"},{"issue":"4","key":"9610_CR45","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1023\/A:1008348704373","volume":"11","author":"R Valenza","year":"2000","unstructured":"Valenza R, Leonardi V, Gebbia V, Agostara B (2000) Gemcitabine and vinorelbine in pretreated advanced breast cancer: a pilot study. Ann Oncol 11(4):495\u2013496","journal-title":"Ann Oncol"},{"issue":"3","key":"9610_CR46","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1046\/j.1524-4741.2002.08308.x","volume":"8","author":"SM Sanal","year":"2002","unstructured":"Sanal SM, Gokmen E, Karabulut B, Sezgin C (2002) Gemcitabine and vinorelbine combination in patients with metastatic breast cancer. Breast J 8(3):171\u2013176","journal-title":"Breast J"},{"key":"9610_CR47","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1023\/A:1013034311284","volume":"70","author":"G Mariani","year":"2001","unstructured":"Mariani G, Tagliabue P, Zucchinelli P, Brambilla C, Demicheli R, Villa E et\u00a0al (2001) Phase I\/II study of gemcitabine in association with vinorelbine for metastatic breast cancer. Breast Cancer Res Treat 70:163\u2013169","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"9610_CR48","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3816\/CBC.2003.n.011","volume":"4","author":"F Lobo","year":"2003","unstructured":"Lobo F, Virizuela JA, Dorta FJ, Florian J, Lomas M, Jimenez E et\u00a0al (2003) Gemcitabine\/vinorelbine in metastatic breast cancer patients previously treated with anthracyclines: results of a phase II trial. Clin Breast Cancer 4(1):46\u201350","journal-title":"Clin Breast Cancer"},{"issue":"16 Suppl","key":"9610_CR49","doi-asserted-by":"crossref","first-page":"A644","DOI":"10.1200\/jco.2005.23.16_suppl.644","volume":"23","author":"DL Graham","year":"2005","unstructured":"Graham DL, Hillman DW, Hobday TJ et\u00a0al (2005) N0234: phase II study of erlotinib (OSI-774) plus gemcitabine as first- or second-line therapy for metastatic breast cancer (MBC). J Clin Oncol 23(16 Suppl):A644","journal-title":"J Clin Oncol"},{"issue":"14 Suppl","key":"9610_CR50","first-page":"A639","volume":"22","author":"CX Ma","year":"2004","unstructured":"Ma CX, Steen P, Rowland KM et\u00a0al (2004) A phase II study of a combination of pemetrexed (Pem) and gemcitabine (Gem) in patients with metastatic breast cancer (MBC): an NCCTG study. J Clin Oncol ASCO Ann Meet Proc (Post-Meet Ed):22(14 Suppl):A639","journal-title":"J Clin Oncol ASCO Ann Meet Proc (Post-Meet Ed):"},{"issue":"1","key":"9610_CR51","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/sj.bjc.6601518","volume":"90","author":"F Cappuzzo","year":"2004","unstructured":"Cappuzzo F, Mazzoni F, Gennari A, Donati S, Salvadori B, Orlandini C et\u00a0al (2004) Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer. Br J Cancer 90(1):31\u201335","journal-title":"Br J Cancer"},{"issue":"2","key":"9610_CR52","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1023\/A:1011945623464","volume":"68","author":"PF Conte","year":"2001","unstructured":"Conte PF, Gennari A, Donati S, Salvadori B, Baldini E, Bengala C et\u00a0al (2001) Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study. Breast Cancer Res Treat 68(2):171\u2013179","journal-title":"Breast Cancer Res Treat"},{"issue":"2 Suppl 3","key":"9610_CR53","first-page":"44","volume":"15","author":"P Sanchez-Rovira","year":"2001","unstructured":"Sanchez-Rovira P, Jaen A, Gonzalez E, Porras I, Duenas R et\u00a0al (2001) Biweekly gemcitabine, doxorubicin, and paclitaxel as first-line treatment in metastatic breast cancer. Final results from a phase II trial. Oncology (Huntingt) 15(2 Suppl 3):44\u201347","journal-title":"Oncology (Huntingt)"},{"issue":"7\u20138","key":"9610_CR54","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1081\/CNV-120005898","volume":"20","author":"M Levin","year":"2002","unstructured":"Levin M, Durgam S, Novetsky A (2002) Cyclophosphamide, doxorubicin, and gemcitabine combination chemotherapy for treatment of metastatic and locally advanced breast cancer. Cancer Invest 20(7\u20138):872\u2013875","journal-title":"Cancer Invest"},{"issue":"Suppl 1","key":"9610_CR55","first-page":"A3046","volume":"88","author":"R Colomer","year":"2004","unstructured":"Colomer R, Mayordomo JI, Calvo I et\u00a0al (2004) HER2 ECD-positive metastatic breast cancer treated with gemcitabine, paclitaxel plus trastuzumab (GTH). Breast Cancer Res Treat 88 Suppl 1:A3046","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"9610_CR56","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1081\/CNV-200032980","volume":"22","author":"G Fountzilas","year":"2004","unstructured":"Fountzilas G, Christodoulou C, Tsavaridis D, Kalogera-Fountzila A, Aravantinos G, Razis E et\u00a0al (2004) Paclitaxel and gemcitabine, as first-line chemotherapy, combined with trastuzumab in patients with advanced breast cancer: a phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG). Cancer Invest 22(5):655\u2013662","journal-title":"Cancer Invest"},{"issue":"12 Suppl 14","key":"9610_CR57","first-page":"33","volume":"17","author":"GW Sledge Jr","year":"2003","unstructured":"Sledge GW Jr (2003) Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer. Oncology (Huntingt) 17(12 Suppl 14):33\u201335","journal-title":"Oncology (Huntingt)"},{"issue":"Suppl","key":"9610_CR58","first-page":"A728","volume":"14","author":"A Polyzos","year":"2004","unstructured":"Polyzos A, Mavroudis D, Boukovinas J et\u00a0al (2004) A multicenter phase II study of docetaxel, gemcitabine and trastuzumab administration as first-line treatment in patients with advanced breast cancer (ABC) overexpressing HER-2. J Clin Oncol ASCO Ann Meet Proc (Post-Meet Ed)(14 Suppl):A728","journal-title":"J Clin Oncol ASCO Ann Meet Proc (Post-Meet Ed)"},{"key":"9610_CR59","unstructured":"Mulkerin D, Dietrich L, Koch P et\u00a0al (2001) A phase II study of Gemcitabine, 5-Fluorouracil, and Leucovorin in Women with Metastatic Breast Cancer (MBC). Proc Am Soc Clin Onc 20(2):43b [A1919]"},{"key":"9610_CR60","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s10549-004-2468-4","volume":"90","author":"SY Rha","year":"2005","unstructured":"Rha SY, Moon YH, Jeung HC, Kim YT, Sohn JH, Yang WI et\u00a0al (2005) Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer. Breast Cancer Res Treat 90:215\u2013221","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"9610_CR61","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1023\/A:1010679127390","volume":"66","author":"CH Smorenburg","year":"2001","unstructured":"Smorenburg CH, Bontenbal M, Seynaeve C, van Zuylen C, de Heus G, Verweij J et\u00a0al (2001) Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane. Breast Cancer Res Treat 66(1):83\u201387","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"9610_CR62","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1054\/brst.2000.0170","volume":"9","author":"T Brodowicz","year":"2000","unstructured":"Brodowicz T, Kostler WJ, Moslinger R, Tomek S, Vaclavik I, Herscovici V et\u00a0al (2000) Single-agent gemcitabine as second- and third-line treatment in metastatic breast cancer. Breast 9(6):338\u2013342","journal-title":"Breast"},{"key":"9610_CR63","unstructured":"Gerson R, Serrano-O A, Villalobos A et\u00a0al (2000) Gemcitabine response in advanced breast cancer in relation to immunohistochemical factors. Proc Am Soc Clin Onc 19(1):145a [A572]"},{"issue":"4","key":"9610_CR64","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1159\/000058524","volume":"60","author":"M Spielmann","year":"2001","unstructured":"Spielmann M, Llombart-Cussac A, Kalla S, Espie M, Namer M, Ferrero JM et\u00a0al (2001) Single-agent gemcitabine is active in previously treated metastatic breast cancer. Oncology 60(4):303\u2013307","journal-title":"Oncology"},{"key":"9610_CR65","unstructured":"Valerio MR, Cicero G, Armata MG et\u00a0al (2001) Gemcitabine (G) in pretreated breast cancer (BC). Proc Am Soc Clin Onc 20(2):51b [A1953]"},{"issue":"1","key":"9610_CR66","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3816\/CBC.2005.n.009","volume":"6","author":"S Modi","year":"2005","unstructured":"Modi S, Currie VE, Seidman AD, Bach AM, Panageas KS, Theodoulou M et\u00a0al (2005) A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane. Clin Breast Cancer 6(1):55\u201360","journal-title":"Clin Breast Cancer"},{"issue":"14 Suppl","key":"9610_CR67","first-page":"A696","volume":"22","author":"K Haider","year":"2004","unstructured":"Haider K, Kornek G, Kwasny W et\u00a0al (2004) Multicenter phase II trial of gemcitabine plus liposomal doxorubicin in chemotherapeutically pretreated patients with advanced breast cancer (ABC). J Clin Oncol ASCO Ann Meet Proc (Post-Meet Ed):22(14 Suppl):A696","journal-title":"J Clin Oncol ASCO Ann Meet Proc (Post-Meet Ed)"},{"issue":"2","key":"9610_CR68","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1023\/A:1008315723253","volume":"10","author":"D Mavroudis","year":"1999","unstructured":"Mavroudis D, Malamos N, Alexopoulos A, Kourousis C, Agelaki S, Sarra E et\u00a0al (1999) Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial. Greek Breast Cancer Cooperative Group. Ann Oncol 10(2):211\u2013215","journal-title":"Ann Oncol"},{"issue":"2 Suppl 5","key":"9610_CR69","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1053\/j.seminoncol.2004.03.022","volume":"31","author":"M Brandi","year":"2004","unstructured":"Brandi M, Vici P, Lopez M, Valerio MR, Giotta F, Gebbia N et\u00a0al (2004) Novel association with gemcitabine and docetaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracyclines: results of a multicenter phase II study. Semin Oncol 31(2 Suppl 5):13\u201319","journal-title":"Semin Oncol"},{"key":"9610_CR70","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/annonc\/mdh028","volume":"15","author":"A Alexopoulos","year":"2004","unstructured":"Alexopoulos A, Tryfonopoulos D, Karamouzis MV, Gerasimidis G, Karydas I, Kandilis K et\u00a0al (2004) Evidence for in vivo synergism between docetaxel and gemcitabine in patients with metastatic breast cancer. Ann Oncol 15:95\u201399","journal-title":"Ann Oncol"},{"issue":"14 Suppl","key":"9610_CR71","first-page":"A710","volume":"22","author":"KS Khoo","year":"2004","unstructured":"Khoo KS, Zaidi M, Srimuninnimit V et\u00a0al (2004) Randomized phase II trial of three gemcitabine (GEM)-taxane combinations in metastatic breast cancer (MBC). J Clin Oncol ASCO Ann Meet Proc (Post-Meet Ed):22(14 Suppl):A710","journal-title":"J Clin Oncol ASCO Ann Meet Proc (Post-Meet Ed)"},{"issue":"12 Suppl 14","key":"9610_CR72","first-page":"26","volume":"17","author":"AM Murad","year":"2003","unstructured":"Murad AM (2003) Paclitaxel and gemcitabine as salvage treatment in metastatic breast cancer. Oncology (Huntingt) 17(12 Suppl 14):26\u201332","journal-title":"Oncology (Huntingt)"},{"issue":"14 Suppl","key":"9610_CR73","first-page":"A724","volume":"22","author":"C Catania","year":"2004","unstructured":"Catania C, Nole F, Balduzzi A, et\u00a0al (2004) Caring for heavily pretreated patients with metastatic breast cancer (MBC): Carboplatin (CBDCA) \u2013 gemcitabine (GCB) combination is effective and well tolerated. J Clin Oncol ASCO Ann Meet Proc (Post-Meet Ed):22(14 Suppl):A724","journal-title":"J Clin Oncol ASCO Ann Meet Proc (Post-Meet Ed)"},{"issue":"14 Suppl","key":"9610_CR74","first-page":"A877","volume":"22","author":"JA Silva","year":"2004","unstructured":"Silva JA, Perez Michel LM, Gallardo Rincon D (2004) Gemcitabine plus carboplatin in recurrent and advanced breast cancer: a phase II trial. J Clin Oncol ASCO Ann Meet Proc (Post-Meet Ed):22(14 Suppl):A877","journal-title":"J Clin Oncol ASCO Ann Meet Proc (Post-Meet Ed)"},{"issue":"14 Suppl","key":"9610_CR75","first-page":"A851","volume":"22","author":"RA Nagourney","year":"2004","unstructured":"Nagourney RA, Link J, Sommers B, et\u00a0al (2004) Carboplatin & gemcitabine repeating doublet in recurrent breast cancer. J Clin Oncol ASCO Ann Meet Proc (Post-Meet Ed):22(14 Suppl):A851","journal-title":"J Clin Oncol ASCO Ann Meet Proc (Post-Meet Ed)"},{"issue":"2","key":"9610_CR76","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3816\/CBC.2004.n.015","volume":"5","author":"FL Nasr","year":"2004","unstructured":"Nasr FL, Chahine GY, Kattan JG, Farhat FS, Mokaddem WT, Tueni EA, et\u00a0al (2004) Gemcitabine plus carboplatin combination therapy as second-line treatment in patients with relapsed breast cancer. Clin Breast Cancer 5(2):117\u201322","journal-title":"Clin Breast Cancer"},{"key":"9610_CR77","unstructured":"Latini L, Torresi U, Valeri M, et\u00a0al (2003) Carboplatin-gemcitabine combination in anthracyclines- and\/or taxanes-resistant metastatic breast cancer. Proc Am Soc Clin Onc 22:80 [A318]"},{"issue":"16 Suppl","key":"9610_CR78","doi-asserted-by":"crossref","first-page":"A837","DOI":"10.1200\/jco.2005.23.16_suppl.837","volume":"23","author":"JE Al\u00e9s-Martinez","year":"2005","unstructured":"Al\u00e9s-Martinez JE, Hern\u00e1ndez R, S\u00e1nchez-Escribano R, et\u00a0al (2005) Tailored low-dose gemcitabine-cisplatin combination is a feasible and effective treatment in heavily pretreated advanced breast cancer patients. J Clin Oncol 23(16 Suppl):A837","journal-title":"J Clin Oncol"},{"issue":"11","key":"9610_CR79","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1200\/JCO.2000.18.11.2245","volume":"18","author":"RA Nagourney","year":"2000","unstructured":"Nagourney RA, Link JS, Blitzer JB, Forsthoff C, Evans SS (2000) Gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed breast cancer patients. J Clin Oncol 18(11):2245\u20139","journal-title":"J Clin Oncol"},{"key":"9610_CR80","unstructured":"Chaudhry S, Abdel-Rahman H, Patil R et\u00a0al (2000) Prospective phase II study of weekly cisplatin-gemcitabine in refractory metastatic breast cancer (RM-BC). Proc Am Soc Clin Onc 19(1):111a [A430]"},{"key":"9610_CR81","unstructured":"Stemmler J, Wohlrab B, Bosse D, et\u00a0al (2003) Gemcitabine plus cisplatin in intensively pretreated metastatic breast cancer: A phase II trial. Proc Am Soc Clin Onc 22:73 [A291]"},{"key":"9610_CR82","unstructured":"Fuentes de la Pena H, Tellez E, Bastarrachea J, et\u00a0al (2001) Gemcitabine plus cisplatin as a palliative treatment in metastatic or refractory breast cancer (MRBC). Proc Am Soc Clin Onc 20(2):60b [A1990]"},{"key":"9610_CR83","unstructured":"Alauddin Z, Fcps S, Rehman E et\u00a0al (2003) Gemcitabine and cisplatin combination chemotherapy as second-line treatment in patients with metastatic breast cancer. Proc Am Soc Clin Onc 22:53 [A212]"},{"issue":"14 Suppl","key":"9610_CR84","first-page":"A774","volume":"22","author":"D Ajarim","year":"2004","unstructured":"Ajarim D, Ezzat A, Bazarbashi S, et\u00a0al (2004) Gemcitabine plus cisplatin combination as second-line treatment in patients with metastatic breast cancer (MBC). J Clin Oncol ASCO Ann Meet Proc (Post-Meet Ed):22(14 Suppl):A774","journal-title":"J Clin Oncol ASCO Ann Meet Proc (Post-Meet Ed)"},{"issue":"Suppl 1","key":"9610_CR85","first-page":"A5064","volume":"88","author":"P Schmid","year":"2005","unstructured":"Schmid P, Heilmann V, Schulz CO, et\u00a0al (2005) Gemcitabine as prolonged infusion and vinorelbine as second-line therapy in metastatic breast cancer: results of a phase-II-study. Breast Cancer Res Treat 88 Suppl 1:A5064","journal-title":"Breast Cancer Res Treat"},{"key":"9610_CR86","unstructured":"Zavettieri M, Raffaele M, Azzarello D et\u00a0al (2003) Phase II study of vinorelbine (V) and gemcitabine (G) in metastatic breast cancer (MBC) patients, previously treated with anthracyclines and \/or taxanes. Proc Am Soc Clin Onc 22:64 [A256]"},{"issue":"1","key":"9610_CR87","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1200\/JCO.2002.20.1.37","volume":"20","author":"GP Stathopoulos","year":"2002","unstructured":"Stathopoulos GP, Rigatos SK, Pergantas N, Tsavdarides D, Athanasiadis I, Malamos NA, et\u00a0al (2002) Phase II trial of biweekly administration of vinorelbine and gemcitabine in pretreated advanced breast cancer. J Clin Oncol 20(1):37\u201341","journal-title":"J Clin Oncol"},{"issue":"4","key":"9610_CR88","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1159\/000070313","volume":"64","author":"E Rossi","year":"2003","unstructured":"Rossi E, Perrone F, Labonia V, Landi G, Nuzzo F, Amabile G et\u00a0al (2003) Is gemcitabine plus vinorelbine active in second-line chemotherapy of metastatic breast cancer? a single-center phase 2 study. Oncology 64(4):479\u2013480","journal-title":"Oncology"},{"issue":"7","key":"9610_CR89","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1023\/A:1008361711049","volume":"11","author":"C Nicolaides","year":"2000","unstructured":"Nicolaides C, Dimopoulos MA, Samantas E, Bafaloukos D, Kalofonos C, Fountzilas G et\u00a0al (2000) Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer progressing after first-line taxane-based chemotherapy: a phase II study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 11(7):873\u2013875","journal-title":"Ann Oncol"},{"issue":"1","key":"9610_CR90","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1023\/A:1022197109592","volume":"78","author":"A Morabito","year":"2003","unstructured":"Morabito A, Filippelli G, Palmeri S, Cascinu S, Ferrau F, Zagonel V et\u00a0al (2003) The combination of gemcitabine and vinorelbine is an active regimen as second-line therapy in patients with metastatic breast cancer pretreated with taxanes and\/or anthracyclines: a phase I-II study. Breast Cancer Res Treat 78(1):29\u201336","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"9610_CR91","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00280-003-0632-x","volume":"52","author":"M Donadio","year":"2003","unstructured":"Donadio M, Ardine M, Berruti A, Ritorto G, Fea E, Mistrangelo M, et\u00a0al (2003) Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer: a phase II study. Cancer Chemother Pharmacol 52(2):147\u201352","journal-title":"Cancer Chemother Pharmacol"},{"issue":"14 Suppl","key":"9610_CR92","first-page":"A759","volume":"22","author":"A Morabito","year":"2004","unstructured":"Morabito A, Carillio G, Bonginelli P, et\u00a0al (2004) Gemcitabine, vinorelbine and trastuzumab combination (GemVinT) as second-third line therapy for HER-2 overexpressing metastatic breast cancer (MBC). J Clin Oncol ASCO Ann Meet Proc (Post-Meet Ed):22(14 Suppl):A759","journal-title":"J Clin Oncol ASCO Ann Meet Proc (Post-Meet Ed)"},{"issue":"2","key":"9610_CR93","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3816\/CBC.2004.n.019","volume":"5","author":"J O\u2019Shaughnessy","year":"2004","unstructured":"O\u2019Shaughnessy J, Vukelja SJ, Marsland T, Kimmel G, Ratnam S, Pippen J (2004) Phase II trial of gemcitabine plus trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer. Clin Breast Cancer 5(2):142\u20137","journal-title":"Clin Breast Cancer"},{"key":"9610_CR94","first-page":"42, A166","volume":"22","author":"C Christodoulou","year":"2003","unstructured":"Christodoulou C, Fountzilas G, Razi E, et\u00a0al (2003) Gemcitabine and trastuzumab combination as salvage treatment in patients with HER 2-positive metastatic breast cancer. Proc Am Soc Clin Onc 22:42, A166","journal-title":"Proc Am Soc Clin Onc"},{"issue":"4","key":"9610_CR95","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3816\/CBC.2002.n.006","volume":"2","author":"HS Salman","year":"2002","unstructured":"Salman HS, Tanaka K, Sparano JA (2002) Phase I\/II trial of gemcitabine plus cyclophosphamide in patients with metastatic breast carcinoma previously treated with taxanes. Clin Breast Cancer 2(4):299\u2013303","journal-title":"Clin Breast Cancer"},{"issue":"16 Suppl","key":"9610_CR96","doi-asserted-by":"crossref","first-page":"A895","DOI":"10.1200\/jco.2005.23.16_suppl.895","volume":"23","author":"J Ahn","year":"2005","unstructured":"Ahn J, Kim J, Lee J et\u00a0al (2005) Phase II study of gemcitabine and capecitabine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes. J Clin Oncol 23(16 Suppl):A895","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"9610_CR97","first-page":"A360","volume":"82","author":"R Andres","year":"2003","unstructured":"Andres R, Mayordomo JI, Polo E et\u00a0al (2003) Activity of gemcitabine plus capecitabine in patients with metastatic breast cancer refractory to anthracyclines and taxanes. Breast Cancer Res Treat 82 Suppl 1:A360","journal-title":"Breast Cancer Res Treat"},{"issue":"Suppl 1","key":"9610_CR98","first-page":"A5063","volume":"88","author":"G P\u00e9rez-Manga","year":"2004","unstructured":"P\u00e9rez-Manga G, L\u00f3pez-Criado P, M\u00e9ndez M, et\u00a0al (2004) Gemcitabine (G) plus capecitabine (C) in previously treated metastatic breast cancer (MBC) patients. Final results from a phase II GOTI trial. Breast Cancer Res Treat 88 Suppl 1:A5063","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"9610_CR99","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1159\/000070312","volume":"64","author":"S Agelaki","year":"2003","unstructured":"Agelaki S, Karyda E, Kouroussis C, Ardavanis A, Kalbakis K, Malas K (2003) Gemcitabine plus irinotecan in breast cancer patients pretreated with taxanes and anthracyclines: a multicenter phase II study. Oncology 64(4):477\u20138","journal-title":"Oncology"},{"issue":"14 Suppl","key":"9610_CR100","first-page":"A829","volume":"22","author":"A Onyenadum","year":"2004","unstructured":"Onyenadum A, Kosmidis P, Aravantinos G, et\u00a0al (2004) Mitoxantrone plus gemcitabine in pretreated patients with advanced breast cancer. J Clin Oncol ASCO Ann Meet Proc (Post-Meet Ed):22(14 Suppl):A829","journal-title":"J Clin Oncol ASCO Ann Meet Proc (Post-Meet Ed):"},{"issue":"4","key":"9610_CR101","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/sj.bjc.6600780","volume":"88","author":"V Lorusso","year":"2003","unstructured":"Lorusso V, Crucitta E, Silvestris N, Catino A, Caporusso L, Mazzei A, et\u00a0al (2003) Phase I\/II study of gemcitabine plus mitoxantrone as salvage chemotherapy in metastatic breast cancer. Br J Cancer 88(4):491\u20135","journal-title":"Br J Cancer"},{"issue":"1","key":"9610_CR102","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1159\/000048243","volume":"62","author":"G Frasci","year":"2002","unstructured":"Frasci G, D\u2019Aiuto G, Comella P, Thomas R, Capasso I, Botti G, et\u00a0al (2002) A phase I-II study on a gemcitabine-cyclophosphamide-fluorouracil\/folinic acid triplet combination in anthracycline- and taxane-refractory breast cancer patients. Oncology 62(1):25\u201332","journal-title":"Oncology"},{"issue":"14 Suppl","key":"9610_CR103","first-page":"A800","volume":"22","author":"DL Stanculeanu","year":"2004","unstructured":"Stanculeanu DL, Cringeanu A, Minea LN, et\u00a0al (2004) Treatment of metastatic breast cancer with alternative vinorelbine and gemcitabine. J Clin Oncol ASCO Ann Meet Proc (Post-Meet Ed):22(14 Suppl):A800","journal-title":"J Clin Oncol ASCO Ann Meet Proc (Post-Meet Ed):"},{"key":"9610_CR104","unstructured":"PDQ [database on the Internet] (2006 Oct 04) Phase III study of two different schedules (weekly and tri-weekly) of combination of gemcitabine and two taxanes in MBC. In: Bethesda (MD): National Cancer Institute. Available from: http:\/\/www.cancer.gov\/Search\/SearchClinicalTrialsAdvanced.asp . Cited 04 Oct 2006"},{"key":"9610_CR105","unstructured":"PDQ [database on the Internet] (2006 Oct 04) Docetaxel vs. docetaxel-gemcitabine in breast cancer. In: Bethesda (MD): National Cancer Institute. Available from: http:\/\/www.cancer.gov\/Search\/SearchClinicalTrialsAdvanced.aspx. Cited 04 Oct 2006"},{"key":"9610_CR106","unstructured":"PDQ [database on the Internet] (2006 Oct 04) Study comparing concomitant docetaxel + gemcitabine to sequential therapy of docetaxel followed by gemcitabine. In: Bethesda (MD): National Cancer Institute. Available from: http:\/\/www.cancer.gov\/Search\/SearchClinicalTrialsAdvanced.asp . Cited 04 Oct 2006"},{"issue":"18S","key":"9610_CR107","doi-asserted-by":"crossref","first-page":"A658","DOI":"10.1200\/jco.2006.24.18_suppl.658","volume":"24","author":"D Mavroudis","year":"2006","unstructured":"Mavroudis D, Ardavanis A, Boukovinas I et\u00a0al (2006) A multicenter randomized study comparing vinorelbine plus gemcitabine versus capecitabine monotherapy as salvage treatment in patients with advanced breast cancer pretreated with taxane and anthracycline chemotherapy: a preliminary report. J Clin Oncol 24(18S):A658","journal-title":"J Clin Oncol"},{"issue":"12","key":"9610_CR108","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1200\/JCO.2002.09.002","volume":"20","author":"J O\u2019Shaughnessy","year":"2002","unstructured":"O\u2019Shaughnessy J, Miles DW, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G et\u00a0al (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20(12):2812\u20132823","journal-title":"J Clin Oncol"},{"issue":"24","key":"9610_CR109","doi-asserted-by":"crossref","first-page":"5542","DOI":"10.1200\/JCO.2005.02.027","volume":"23","author":"SE Jones","year":"2005","unstructured":"Jones SE, Erban J, Overmoyer B, Budd GT, Hutchins L, Lower E et\u00a0al (2005) Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 23(24):5542\u20135551","journal-title":"J Clin Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-007-9610-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-007-9610-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-007-9610-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T00:51:44Z","timestamp":1683852704000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-007-9610-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5,26]]},"references-count":109,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["9610"],"URL":"https:\/\/doi.org\/10.1007\/s10549-007-9610-z","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,5,26]]}}}